An herbal medication as complementary conventional chemotherapy for gastric and esophageal cancer patients

Phase 3

• Conditions: Condition 1: Oesophagus cancer. Condition 2: Gastric cancer.; Malignant neoplasm of stomach; Malignant neoplasm of oesophagus

• Registration Number: IRCT2016092529963N1
• Lead Sponsor: Vice chancellor for research ,Digestive Diseases Research Institute, Tehran University of Medical Sc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 83

Inclusion Criteria

Histologically confirmed esophageal squamous cell carcinoma or Adenocarcinoma of the distal esophagus or gastric cancer; The Largest diameter of the lesion = 10 mm based on Spiral-CT Scan; The absence of brain metastases; Karnofsky Performance status scale =70%; Age>=18
Exclusion criteria:
Congestive heart failure (EF <= 40%); Medical history of myocardial infarction during the past 6 months; Concurrent use of Vasodilators; Uncontrolled arrhythmias; Complications in central nervous system (Spinal cord and brain); Medical history of CVA, stroke within the last 6 months; Respiratory failure (PO2<= 50 mmHg) for any reason; Level of liver enzymes (AST, ALT) > 5 folds the normal limits; Bilirubin serum = 5 mg per deciliter; serum Creatinine level > 2 milligrams per deciliter); WBC < 2500 per cubic millimeter of blood; Platelet count < 100,000 per cubic millimeter of blood ; Pregnant and nursing mothers; Any type of active infection ; IV drug users ; Major psychological disorders

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified